RankingsPricing
  1. US-listed companies
  2. ALNYLAM PHARMACEUTICALS, INC.
  3. Financials
  4. Cash from investing

ALNYLAM PHARMACEUTICALS, INC.ALNY

Market cap
$56.6B
P/E ratio
SummaryFinancials
Period EndCash from investing (Million USD)YoY (%)
Dec 31, 2024-117-65.26%
Dec 31, 2023-336-298.61%
Dec 31, 2022169-161.97%
Dec 31, 2021-273-37.25%
Dec 31, 2020-436+4.27%
Dec 31, 2019-418-253.03%
Dec 31, 2018273-194.00%
Dec 31, 2017-290-303.63%
Dec 31, 2016143-144.38%
Dec 31, 2015-321-41.45%
Dec 31, 2014-549+320.53%
Dec 31, 2013-131-3967.96%
Dec 31, 20123-95.88%
Dec 31, 201182+359.46%
Dec 31, 201018

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)